| DEALFLOWUPDATE Issue #21. Friday, December 7 |
Hello Everyone, Hope everyone had a great Thanksgiving…the Christmas holiday is now right around the corner… For this edition of the Zoic newsletter, we’ll be discussion two main subjects in our deals section. The first is the continuing trend of acquisitions and partnerships in diagnostics, especially biofluid (such as blood) testing and genetic analysis. This is also a good example of the merging of the tech and medical device industries, both from the investment side and the company side, as the data is extremely valuable to both. The second category is just how diverse the potential medical device applications are and how even niche, small applications are regularly involved in acquisitions and raises. Where we specialize in, though, is seeing where even a initial niche application can lead to a whole host of additional indications, because of the platform nature of the technology. -Neal P.S. Our readership continues to grow! please subscribe if you’re new and continue to share with others on social media. Connect with us, we would love to hear from you! |
Dealflow Illumina to buy rival Pacific Biosciences in $1.2 billion deal In our first example of diagnostics, a recent acquisition shows how strong the market is in diagnostic technologies, particularly in gene sequencing. Sequencing takes the information gathered from binary “yes/no” tests that search only for a specific sequence to a whole picture story that can reveal much more information. Initial testing of that binary nature could be started at the home level, given the right technology, with follow-up tests conducted with sequencing systems in more formal laboratories. Read More  Neuropointdx launches blood test to help diagnose autism at earlier stage And in the second example, more and more conditions are being brought under the umbrella of early diagnostic testing. For example, with autism. We will see more and more tests come about that are specific to a particular condition. What will be interesting is how these tests can be integrated into standard panels, as it can be confusing already with the multiude of test and devices, especially as they are being pushed to consumers. Read More Spotlight  #ZoicNews Zoic Capital recently held its Intellectual Property workshop led by Zoic IP Partner, Eugene Shteyn. Providing IP strategy for Zoic he led our family of portfolio companies into long term IP strategic thinking and business strategy. An experienced inventor, entrepreneur, IP licensing professional, and educator, Eugene and Zoic Capital help companies improve their innovation success rate. To learn more about Eugene’s systematic approach check out his book, “Scalable Innovation: A Guide for Inventors, Entrepreneurs, and IP Professionals.” Eugene Shteyn PhD, Zoic Capital Partner of IP, discusses the importance of IP strategy for seed stage and startup companies and working towards results in accelerated innovation development and evaluation cycles. (video below) David Lapointe, President and CEO of Optina Dx, reflects on the IP Workshop held by Zoic Capital and how it provides specific tools for quickly identifying essential present and missing elements of systems underpinning high-value problems and their proposed solutions. (video below) ShareTweetForward What We’re ReadingWIR Canada Welcomes AI, But Not All AI Researchers NYT China’s 2018 VC Binge Could Turn Into a Hangover REC Why Lyft Had To Beat Uber To An IPO Filing RCD Why No One Really Knows How Many Jobs Automation Will Replace Connect With Zoic Capital |
| The Biweekly Dealflow Update, curated by the team at Zoic Capital. |
Recommended For You
Neuralink and the Long Path to Approval
Neuralink and the Long Path to Approval
zoicaccountSeptember 11, 2021
As 2021 begins, we reflect on scientific advancements in 2020 spurred by the COVID-19 crisis
As 2021 begins, we reflect on scientific advancements in 2020 spurred by the COVID-19 crisis
zoicaccountJanuary 31, 2021
COVID-19, Alzheimer’s, and Cancer Testing
COVID-19, Alzheimer’s, and Cancer Testing
zoicaccountDecember 7, 2020